Get the Stockscreener App
11.41
6.24%
-0.76
After Hours:
11.41
Benitec Biopharma Inc stock is traded at $11.41, with a volume of 432.41K.
It is down -6.24% in the last 24 hours and up +7.04% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$12.17
Open:
$12.02
24h Volume:
432.41K
Relative Volume:
8.75
Market Cap:
$264.90M
Revenue:
$59,000
Net Income/Loss:
$-21.81M
P/E Ratio:
-0.6735
EPS:
-16.9418
Net Cash Flow:
$-18.07M
1W Performance:
-3.06%
1M Performance:
+7.04%
6M Performance:
+81.11%
1Y Performance:
+277.81%
1-Day Range:
$11.41
$12.40
1-Week Range:
$11.41
$13.29
52-Week Range:
$2.69
$13.29
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
11.41 | 264.90M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
Equities Analysts Issue Forecasts for BNTC Q2 Earnings - Defense World
Q2 Earnings Estimate for BNTC Issued By HC Wainwright - MarketBeat
Where are the Opportunities in (BNTC) - Stock Traders Daily
Hedge funds investors own a significant stake of 38% in Benitec Biopharma Inc. (NASDAQ:BNTC) - Yahoo Finance
Benitec Biopharma stock soars to 52-week high of $13.29 - Investing.com
Benitec Biopharma (NASDAQ:BNTC) Now Covered by HC Wainwright - Defense World
Benitec Biopharma initiated with a Buy at H.C. Wainwright - Yahoo Finance
Benitec Biopharma's SWOT analysis: gene therapy stock shows promise in OPMD - Investing.com
Benitec Biopharma announces executive team changes - Investing.com
Benitec Biopharma (NASDAQ:BNTC) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Coverage Initiated by Analysts at HC Wainwright - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Appoints New Chief Operating Officer and Makes Changes to Executive Officers’ Roles and Compensation - Defense World
Benitec Biopharma announces executive team changes By Investing.com - Investing.com UK
Short Interest in Benitec Biopharma Inc. (NASDAQ:BNTC) Grows By 6.9% - MarketBeat
Robert W. Baird Begins Coverage on Benitec Biopharma (NASDAQ:BNTC) - Defense World
Benitec Biopharma Shakes Up Management Team - MarketWatch
Baird Initiates Coverage of Benitec Biopharma (BNTC) with Outperform Recommendation - MSN
Benitec Biopharma (NASDAQ:BNTC) Coverage Initiated at Robert W. Baird - MarketBeat
Baird sets $30 target on Benitec BioPharma, cites gene therapy By Investing.com - Investing.com UK
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
Benitec Biopharma approves preferred stock issuance By Investing.com - Investing.com Canada
Benitec Biopharma approves preferred stock issuance - Investing.com
Benitec Biopharma stock soars to 52-week high of $12.95 By Investing.com - Investing.com Canada
Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? - Yahoo Finance
When (BNTC) Moves Investors should Listen - Stock Traders Daily
Benitec Biopharma shareholders approve key proposals By Investing.com - Investing.com Canada
JANUS HENDERSON GROUP PLC Increases Stake in Benitec Biopharma I - GuruFocus.com
Brokerages Set Benitec Biopharma Inc. (NASDAQ:BNTC) PT at $22.60 - MarketBeat
Benitec Biopharma Inc. (NASDAQ:BNTC) Given Consensus Rating of “Buy” by Analysts - Defense World
Guggenheim Reaffirms “Buy” Rating for Benitec Biopharma (NASDAQ:BNTC) - Defense World
Benitec Biopharma's SWOT analysis: promising OPMD treatment lifts stock outlook - Investing.com India
Suvretta Capital Management LLC Has $81.14 Million Stake in Benitec Biopharma Inc. (NASDAQ:BNTC) - MarketBeat
Benitec Biopharma to Participate in Upcoming Investor Conferences in December - GlobeNewswire
Benitec Biopharma to Present at Major Healthcare Conferences in December | BNTC Stock News - StockTitan
Suvretta Capital Management's Strategic Acquisition in Benitec B - GuruFocus.com
How To Trade (BNTC) - Stock Traders Daily
Simplify Asset Management Inc. Increases Position in Benitec Biopharma Inc. (NASDAQ:BNTC) - MarketBeat
Benitec Biopharma Inc reports results for the quarter ended September 30Earnings Summary - XM
Benitec Biopharma Inc. (BNTC) Quarterly 10-Q Report - Quartzy
Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Be - GuruFocus.com
Benitec Biopharma executives receive performance bonuses - Investing.com
Benitec Biopharma Awards Bonuses to Key Executives - TipRanks
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update - The Manila Times
Benitec's BB-301 Shows Major Clinical Gains: 35-40% OPMD Symptom Improvement | BNTC Stock News - StockTitan
Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Update - MarketBeat
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives $22.60 Average Target Price from Analysts - MarketBeat
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Average Recommendation of “Buy” from Analysts - Defense World
(BNTC) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference - GlobeNewswire
Long Term Trading Analysis for (BNTC) - Stock Traders Daily
Piper Sandler Initiates Coverage of Benitec Biopharma (BNTC) with Overweight Recommendation - MSN
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Benitec Biopharma Inc Stock (BNTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 20 '24 |
Buy |
10.22 |
27,436 |
280,396 |
7,920,175 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 19 '24 |
Buy |
9.73 |
14,000 |
136,220 |
7,895,815 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):